The associations of MAOA/MAOB genetic variants with clinical improvement after ATD treatment and MAO activity, which modulates monoamine concentrations—common targets of ATD therapy—qualify them as potential biomarkers for clinical improvement following ATD treatment in MDD. Here, MAOB is linked to Jeune syndrome.